Cue Health Confirms Covid-19 Tests Can Detect Omicron Variant
Cue Health announced it has completed an analysis of the SARS-CoV-2 B.1.1.529 variant, designated by the World Health Organization as Omicron. Using information from the GISAID database, Cue has determined its COVID-19 tests, which uses molecular (NAAT) technology, can detect the Omicron variant. Specifically, Cue found that 99.2% of the available 127 published sequences are a perfect match to the primers used in the Company's tests. Cue's easy-to-use, portable COVID-19 tests provide highly accurate, lab-quality results directly to connected mobile smart devices in about 20 minutes, and it can be used on adults and children (2 years and over), with or without symptoms, wherever they are. Cue's team of scientists and bioinformatic experts implemented a surveillance program during the early stages of the pandemic to monitor and analyze all relevant SARS-CoV-2 variant sequences globally. These sequences are routinely compared to the primers in Cue's COVID-19 test to determine if any mutations are present that could affect the sensitivity or specificity of Cue's test. Cue's tests work by targeting a region of the nucleocapsid gene (n gene) that is highly conserved, and Company scientists have found that the test's accuracy has remained unaffected by the mutations in the Omicron variant and other variants of concern to date. Cue and Helix, a leading genomics company that provides nationwide surveillance of respiratory disease, announced this month a new collaboration to conduct a research study to evaluate variant data. This sequencing effort will allow Cue to contribute to public health sequencing and surveillance efforts by allowing users who obtain positive COVID-19 test results at home to opt in and consent to have their samples rapidly sequenced and shared with public health sequencing repositories like GISAID. Cue's collaboration with Helix further builds on Cue's previously announced real-time variant tracking and sequencing solution, which utilizes AI and ML from Google Cloud to add predictive capabilities to the Cue platform. Earlier this month, Cue launched its direct-to-consumer (DTC) virtual health platform in the United States, making Cue's first-of-its-kind molecular COVID-19 test available through Cue's new eCommerce site and in-app shop. Cue's new membership offering — Cue+™ — offers members 24/7 on-demand access to board certified physicians, e-prescription services, CDC-compliant test results for travel through in-app video proctoring, and same-day delivery of Cue products in a number of major markets. In the U.S., the Cue COVID-19 Test for Home and Over The Counter (OTC) Use was the first molecular test to receive FDA Emergency Use Authorization (EUA) for at-home and over-the-counter use without a prescription. This followed an EUA from the FDA in June 2020 for professional point-of-care use.